Sanofi struck a deal to acquire rights to a phase‑1 trispecific T‑cell engager from Kali Therapeutics, providing $180 million upfront as part of a broader agreement that can reach roughly $1.2 billion in milestones. The move marks Sanofi’s renewed strategic push into engineered T‑cell engager modalities. The pact signals big‑pharma appetite to re‑enter multispecific T‑cell engager programs and accelerates development resources for Kali’s early‑stage trispecific candidate. Sanofi’s deal structure and near‑term payment underscore the commercial potential firms assign to next‑generation T‑cell engager platforms.